Research ArticleBasic Science Investigations
Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer
Sandra Heskamp, Peter Laverman, Daniel Rosik, Frederic Boschetti, Winette T.A. van der Graaf, Wim J.G. Oyen, Hanneke W.M. van Laarhoven, Vladimir Tolmachev and Otto C. Boerman
Journal of Nuclear Medicine January 2012, 53 (1) 146-153; DOI: https://doi.org/10.2967/jnumed.111.093047
Sandra Heskamp
Peter Laverman
Daniel Rosik
Frederic Boschetti
Winette T.A. van der Graaf
Wim J.G. Oyen
Hanneke W.M. van Laarhoven
Vladimir Tolmachev
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 1
January 1, 2012
Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer
Sandra Heskamp, Peter Laverman, Daniel Rosik, Frederic Boschetti, Winette T.A. van der Graaf, Wim J.G. Oyen, Hanneke W.M. van Laarhoven, Vladimir Tolmachev, Otto C. Boerman
Journal of Nuclear Medicine Jan 2012, 53 (1) 146-153; DOI: 10.2967/jnumed.111.093047
Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer
Sandra Heskamp, Peter Laverman, Daniel Rosik, Frederic Boschetti, Winette T.A. van der Graaf, Wim J.G. Oyen, Hanneke W.M. van Laarhoven, Vladimir Tolmachev, Otto C. Boerman
Journal of Nuclear Medicine Jan 2012, 53 (1) 146-153; DOI: 10.2967/jnumed.111.093047
Jump to section
Related Articles
Cited By...
- 18F-AlF-Labeled Biomolecule Conjugates as Imaging Pharmaceuticals
- In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
- Synthesis and Characterization of 18F-Interleukin-8 Using a Cell-Free Translation System and 4-18F-Fluoro-L-Proline
- Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice
- Al18F Labeling of Affibody Molecules
- Reply: Al18F Labeling of Affibody Molecules
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling
- Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
- Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer